Thus, the article focuses on the most relevant in vivo preclinical studies evaluating the effect of DYRK1A inhibition in mouse models of DS and more recently in human induced pluripotent stem cells from patients with DS (DS-iPSCs). This evidence concerns the gene DYRK1A and Dravet syndrome.